Value added: Digital health, pharma companies collaborate
This article was originally published in Scrip
Pharmaceutical companies have to think beyond the pill – or injection – if they want their 15 years of drug development and $1.5 billion investment in new medicines to result in payer reimbursement, and digital health options are emerging to help pharma add value.
You may also be interested in...
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.